The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Unmet needs in MDS: treating relapse after alloHSCT & TP53-mutated disease
Hege Garelius
• 9 Jun 2022
Hege Garelius, MD, Sahlgrenska University Hospital, Göteborg, Sweden, outlines unmet needs in myelodysplastic syndromes (MDS), which include the treatment of patients who relapse following allogeneic hematopoietic stem cell transplantation (alloHSCT), and the management of patients with TP53 mutations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
